Transmissible Spongiform Encephalopathy

Technology shown to remove transmissible spongiform encephalopathy infectivity

Published in Blood Weekly, November 17th, 2005

Pathogen Removal and Diagnostic Technologies Inc. (PRDT), a joint venture between ProMetic Life Sciences Inc. (PLI.SV) and the American Red Cross, announced the results of a major study showing that its patented ligand technology removes all detectable blood-borne transmissible spongiform encephalopathy (TSE) infectivity from whole blood.

According to the current results from the endogenous (blood-borne) infectivity study cosponsored by PRDT, its partner MacoPharma, and ProMetic, none of the 100 lab animals (hamsters) injected with leukoreduced scrapie infected whole blood, previously filtered through devices containing the PRDT resin, developed signs of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry